Royal College of Physicians   Report issue

Academic/Hospital Phase 2
Founded: London United Kingdom (1518)

Organization Overview

First Clinical Trial
2006
NCT00305591
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylcysteine (mucomyst) (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (2)

glucagon-like peptide-1 (1 trial)

ornithine aspartate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Lung Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4